03.11.2006 14:00:00

Merck & Co., Inc. Introduces New 14th Edition of The Merck Index, with Companion CD-ROM

The Merck Index, a one-volume encyclopedia of chemicals, drugs and biologicals, is now available in an updated 14th edition. The new volume was unveiled this week at the national meeting of the American Association of Pharmaceutical Scientists. The Merck Index has been "chemistry's constant companion" since it was first published in 1889. More than 1 million copies of the text have been sold since then. Known throughout the world as the most definitive reference for chemists, biologists and pharmacists, The Merck Index contains more than 2,500 pages with 10,200 monographs, each describing a single substance or small groups of related compounds. The reference features chemical and brand names, molecular weights and formulas, citations to scientific literature, depictions of structures, physical and toxicity data, details on commercial and therapeutic uses, and up-to-date U.S. regulatory information on carcinogens and controlled substances. For the first time, each copy of The Merck Index will come with a companion CD-ROM and a one-year personal subscription to The Merck Index – Internet Edition, which will provide immediate online access to updates. The CD contains all the contents of the 14th edition plus nearly 1,000 monographs archived from previous editions and can be searched by keywords, references, and numerical properties. What’s New The 14th edition features: Approximately 700 new and completely revised monographs on chemical and biological substances Increased focus on "Green Chemistry" and compounds of environmental significance Expanded coverage of physical property information for the bench scientist Molecular weights for all compounds and derivatives Extensively revised supplemental tables that now provide acronyms, vaccines and physical constants Updated information on Organic Name Reactions and Reagents Not-for-Profit Service In addition to The Merck Index, Merck also publishes The Merck Manual of Diagnosis and Therapy, The Merck Manual of Geriatrics, The Merck Manual of Medical Information – Second Home Edition, The Merck Manual of Health and Aging, and The Merck Veterinary Manual. All books from Merck are published as a not-for-profit service. The 14th edition of The Merck Index costs $125.00 and can be ordered at www.merckbooks.com. About Merck Merck & Co., Inc. is a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck currently discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The Company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines but help deliver them to the people who need them. Merck also publishes unbiased health information as a not-for-profit service. For more information, visit www.merck.com. Forward-Looking Statement This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Merck & Co., Inc. undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the cautionary statements in Item 1 of Merck's Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K, which the company incorporates by reference.

JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.

Analysen zu Merck Co.mehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Merck Co. 97,90 0,72% Merck Co.

Indizes in diesem Artikel

Dow Jones 44 722,06 -0,31%
S&P 500 5 998,74 -0,38%
S&P 100 2 883,15 -0,41%
NYSE US 100 17 376,20 -0,02%